Insider Transactions in Q1 2023 at Gilead Sciences, Inc. (GILD)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2023
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,126
-8.03%
|
$477,828
$78.99 P/Share
|
|
Mar 10
2023
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,017
-3.6%
|
$1,107,343
$79.5 P/Share
|
|
Mar 10
2023
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,288
+3.79%
|
-
|
|
Mar 10
2023
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,328
-6.53%
|
$420,912
$79.5 P/Share
|
|
Mar 10
2023
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,454
+6.71%
|
-
|
|
Mar 10
2023
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-2.97%
|
$63,279
$79.5 P/Share
|
|
Mar 10
2023
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
2,921
+5.26%
|
-
|
|
Mar 10
2023
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,116
-5.86%
|
$404,164
$79.5 P/Share
|
|
Mar 10
2023
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,976
+6.01%
|
-
|
|
Mar 10
2023
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,849
-4.18%
|
$383,071
$79.5 P/Share
|
|
Mar 10
2023
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,419
+4.35%
|
-
|
|
Mar 09
2023
|
Kevin E Lofton Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,442
+50.0%
|
$438,984
$52.38 P/Share
|
|
Mar 01
2023
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,984
-15.62%
|
$1,025,736
$79.96 P/Share
|
|
Mar 01
2023
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,842
-1.33%
|
$382,518
$79.59 P/Share
|
|
Mar 01
2023
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,362
+3.02%
|
-
|
|
Feb 15
2023
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
376
+0.35%
|
$21,056
$56.38 P/Share
|
|
Feb 15
2023
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
376
+0.45%
|
$21,056
$56.38 P/Share
|
|
Feb 15
2023
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Grant, award, or other acquisition
|
Direct |
376
+50.0%
|
$21,056
$56.38 P/Share
|
|
Feb 06
2023
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
565
-1.73%
|
$48,590
$86.36 P/Share
|
|
Feb 06
2023
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,864
+5.41%
|
-
|
|
Feb 06
2023
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
531
-0.5%
|
$45,666
$86.36 P/Share
|
|
Feb 06
2023
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,817
+1.69%
|
-
|
|
Jan 24
2023
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,327
-12.85%
|
$1,287,468
$84.02 P/Share
|
|
Jan 24
2023
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,202
+24.96%
|
-
|
|
Jan 24
2023
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
59,078
-14.34%
|
$4,962,552
$84.02 P/Share
|
|
Jan 24
2023
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
215,017
+23.53%
|
-
|
|
Jan 24
2023
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,325
-16.71%
|
$1,287,300
$84.02 P/Share
|
|
Jan 24
2023
|
Johanna Mercier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,394
+32.37%
|
-
|
|
Jan 24
2023
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,749
-17.66%
|
$1,490,916
$84.02 P/Share
|
|
Jan 24
2023
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,359
+32.31%
|
-
|
|
Jan 24
2023
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,244
-3.89%
|
$104,496
$84.02 P/Share
|
|
Jan 24
2023
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
5,884
+8.7%
|
-
|